Close

AstraZeneca (AZN) Gains on Novartis (NVS) Chatter

Go back to AstraZeneca (AZN) Gains on Novartis (NVS) Chatter

AstraZeneca (AZN) Announces FDA Acceptance of Sodium Zirconium Cyclosilicate NDA Resubmission

October 18, 2016 7:51 AM EDT

AstraZeneca (NYSE: AZN) announced that the US Food and Drug Administration (FDA) has accepted a complete re-submission of a New Drug Application (NDA) for sodium zirconium cyclosilicate (ZS-9), a potential new medicine for the treatment of hyperkalaemia (high potassium level in the blood serum) by ZS Pharma, a... More

AstraZeneca (AZN) declines to comment on M&A speculation - Bloomberg, citing spokesperson

October 17, 2016 10:48 AM EDT

AstraZeneca (NYSE: AZN) declines to comment on M&A speculation - Bloomberg, citing spokesperson

... More

AstraZeneca (AZN) October calls active

October 17, 2016 10:29 AM EDT

AstraZeneca (NYSE: AZN) October 30.5 and 31 calls are active on total call volume of 7,200 contacts (60 puts). October call option implied volatility is at 34, November is at 30; compared to its 52-week range of 33 to 74.

... More